A novel, non-hallucinogenic, experimental drug shows statistically significant, rapid, and durable improvement in PTSD symptom severity in a phase 2 trial.

Neuroscientists identify a CRF-neuron "switch" in the brain's BNST region that, when activated, allows for significantly faster unlearning of fear responses.

MIAMI, FLORIDA / ACCESS Newswire / September 16, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral therapeutics ...

Post Traumatic Stress Disorder (PTSD) has been invoked to help explain many aspects of human behavior, including violence. The April 2 shooting at Fort Hood in Texas that left three dead and sixteen ...